SAREPTA THERAPEUTICS, INC. Q4 AND FULL YEAR 2019 EARNINGS CONFERENCE CALL
FORWARD-LOOKING STATEMENTS

In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this conference call. Any statements made by Sarepta that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs including: our vision to become one of the world's leaders in precision genetic medicine to treat rare disease and our intention to realize much of that vision in 2020 through 2021; our 2020 guidance for Exondys 51 of $420 million to $430 million; our goal to increase access for VYONDYS 53 and to work toward an all-inclusive coverage; the expectation that the Vyondys 53 launch will be measured and steady, with a curve similar to the launch curve of Exondys 51; the expectation to have three therapies capable of treating approximately 30% of the Duchenne community in the United States with double the number of patients who may benefit from our PMO technology versus Exondys 51 alone; the potential of our 6 LGMD programs to provide treatments to over 70% of patients with LGMD; our goal to make a dose selection for LGMD2E in 2020; the potential benefits of our collaboration with Roche; Sarepta being well positioned with the resources, the assets and the talent to drive its ambitious strategy towards success; PPMO's potential to be a significant advancement in our RNA technology; our beliefs regarding the mix of commercial to Medicaid patients; VYONDYS 53's potential to serve approximately 8% of the Duchenne community; the potential launch of casimersen; and current plans and expected milestones, including the plan that the last patient/last visit in study 102 for SRP-9001 will occur in December 2020, releasing the results from study 102 for SRP-9001 in the first quarter of 2021, commencing our commercial supply trial (study 301) for SRP-9001, having GMP material for SRP-9001 released in July 2020, announcing expression and safety results for LGMD2E in the Q2 2020, making a dose selection decision for LGMD2E in the Q3 2020, completing the assay and process development work for LGMD2E with the goal of having GMP material available in time to commence a trial in early 2021, commencing a trial with commercial process material for LGMD2E in early 2021, subject to regulatory feedback, completing all dosing in our MPS3A gene therapy program by mid-2020, commencing proof-of-concept study for CMT in 2020, completing building our Gene Editing Innovation Center in 2020, completing our rolling submission for Casimersen in Q2 2020, releasing results from our PROMOVI study in March 2020, and having dosing and safety insight on PPMO in 2020.

These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to meet expectations with respect to sales of our products or attain the anticipated net revenues, profitability or positive cash-flow from operations; the commercial launch for VYONDYS 53 in the U.S. may not be successful for various reasons including the actual market size and drug supply needed may not be consistent with the company's expectations, the degree to which VYONDYS 53 is accepted by patients and prescribed by physicians, manufacturing limitations, and competitive, reimbursement and regulatory conditions that could negatively impact the commercial launch of VYONDYS 53; we may not be able to comply with FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; Sarepta's dependence on certain manufacturers to produce its products and product candidates, including any inability on Sarepta's part to accurately anticipate product demand and timely secure manufacturing capacity, may impair the availability of product to successfully support various programs; success in preclinical testing and early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; our data for casimersen, SRP-5051, SRP-9001, the LGMD programs and/or other programs may not be sufficient for obtaining regulatory approval; the expected benefits and opportunities related to our agreements with our strategic partners may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreements, challenges and uncertainties inherent in product research and development and manufacturing limitations; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of Sarepta's control, including possible limitations of company financial and other resources, manufacturing limitations, reimbursement hurdles and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta's product candidates; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2019 and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.